Aridis Pharmaceuticals, Inc. (ARDS)

0,0600 +0,0034 (+6,01%) Alla chiusura: 03:47PM EDT

Aridis Pharmaceuticals, Inc.

983 University Avenue
Building B
Los Gatos, CA 95032
United States
408 385 1742
https://www.aridispharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 37

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Eric J. Patzer Ph.D.	Founder & Executive Chairman	240k	N/D	1949
Dr. Vu L. Truong Ph.D.	Founder, CEO, Chief Scientific Officer & Director	631,65k	N/D	1964
Dr. Hasan Jafri M.D.	Chief Medical Officer	559,36k	N/D	1967
Ms. Tamara S. Allen	Vice President of Finance	N/D	N/D	1967
Mr. Jeffrey J. Fessler Esq., J.D.	Acting General Counsel	N/D	N/D	1963

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

Governance aziendale

L'ISS Governance QualityScore di Aridis Pharmaceuticals, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.